Search

Displaying results 2861 - 2870 of 10000 in total
  1. Drug

    Mangafodipir

    go.drugbank.com/drugs/DB06796
    ApprovedInvestigationalWithdrawn

    The contrast agent is present as mangafodipir trisodium marketed under the name Teslascan. … Teslascan has been removed from the Drug Product List by FDA in 2003, and withdrawn from the European market in 2012.

  2. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    [L10145] The FDA approved Selinexor in June 2019. … [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at

  3. Drug

    Bentiromide

    go.drugbank.com/drugs/DB00522
    ApprovedWithdrawn

    Cases of headache and gastrointestinal disturbances have been reported with the use of bentiromide. Bentiromide is currently not available in the U.S. or Canada. … Bentiromide is a dipeptide that is used in the bentiromide test, which is a screening test for evaluating pancreatic exocrine function and monitoring the adequacy of supplemental pancreatic therapy.

  4. Drug

    Cyproheptadine

    go.drugbank.com/drugs/DB00434
    ApprovedInvestigational

    [L32474] It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation[L32519] and its off-label use in the treatment of serotonin syndrome.

    Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor AntagonistsSynonyms: 1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
  5. Drug

    Bromfenac

    go.drugbank.com/drugs/DB00963
    ApprovedWithdrawn

    Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] … Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation.

  6. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. … The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.

  7. Drug

    Nitisinone

    go.drugbank.com/drugs/DB00348
    Approved

    It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria. It is sold under the brand names Orfadin and Harliku. [L53253, L53258]

  8. Drug

    Vildagliptin

    go.drugbank.com/drugs/DB04876
    ApprovedInvestigational

    [L32813] Vildagliptin is currently under investigation in the US. … [A232488] Oral vildagliptin was approved by the European Medicines Agency in 2008 for the treatment of type II diabetes mellitus in adults as monotherapy or in combination with [metformin], a sulfonylurea

    Mixtures: VILDAGLIPTIN E METFORMINA SANDOZ, VILDAGLIPTIN E METFORMINA SANDOZ
  9. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary to intestinal dysfunction. … The lysosomal acid lipase (LAL) enzyme is found in lysosomes and is primarily responsible for the metabolism of lipids, and its absence or deficiency results in the accumulation of lipids in various organs

  10. Drug

    Cinacalcet

    go.drugbank.com/drugs/DB01012
    ApprovedInvestigational

    It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure. … Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe.

    Categories: Calcium-sensing Receptor Agonist, Increased Calcium-sensing Receptor Sensitivity